Drugs / D702
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05881707 | Jul → Sep 2023 | hypertensive disorder | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT06121518 | Jul 2023 → Mar 2024 | essential hypertension | Chong Kun Dang Pharmaceutical | Completed | Met primary |
| Phase 3 | NCT05931224 | Jun 2023 → May 2024 | essential hypertension | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05881707 ↗ |
| Route | Oral | “a single oral dose” NCT05881707 ↗ |